Kurt Schwinghammer, Ph.D.

Topics in This Section

Clinical Trials

Clinical Trials

Phase 1 Clinical Trials
Read more »

Biosample Repository

Biosample Repository

Collection and distribution of human subject biosamples.
Read more »

By The Numbers

A Century of Excellence

National rankings, accreditations, awards. The numbers are in your favor.
Read more »

Faculty Summaries
Kurt Schwinghammer

Kurt A. Schwinghammer joined FCCC in April 2007 and became VP of the R&D Alliances Office in September 2009. He works closely with the Office of the President including all "C-level" executives to develop a strategy to effectively capitalize on Fox Chase's preclinical and clinical research capabilities. Kurt is pivotal in the development of preclinical and clinical strategic alliances with industry, and the development of all such business relationships. Among countless Kurt’s achievements he established Fox Chase International to initiate and maintain relationships with off-shore hospitals that require greater oncology skills, expertise and training; and serves as an active board member of two Fox Chase start-up companies: Dynamis Therapeutics and Nexus Pharmaceuticals.

Kurt was awarded a Ph.D. and M.S. in biological sciences from the University of Kentucky and a B.S. from Purdue University. He is an active member of the Association of University Technology Managers and the Licensing Executives Society. Kurt was previously Deputy Managing Director, Technology Transfer and Director of Licensing at The University of Pennsylvania’s Center for Technology Transfer (CTT) where he managed the commercialization and licensing efforts of all Licensing and Marketing Directors, and where he worked closely with the Director of Startup Companies to determine which technologies could form the basis for new companies. For five years prior to joining CTT, Kurt was Director of the Department of Technology Transfer at The Children’s Hospital of Philadelphia (CHOP), where he managed the Offices of Corporate Alliances, Intellectual Property, and Technology Commercialization. After several years as a research scientist and research manager in industry, his segue into technology transfer was as Technology Acquisition Manager for American Cyanamid Company where he supported research, development, marketing and sales through identification and acquisition of technologies, leads and product opportunities that fit business objectives of the company. Additionally, he identified companies that were of corporate strategic interest and conducted diligence around their acquisition.